The live and archived webcast of this event can be accessed through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events ...

- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical ...

- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on ...

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which ...

Padarn Therapeutics Inc. has described CDK2/cyclin A2 and CDK1/cyclin A2 inhibitors reported to be useful for the treatment of cancer.

Acrivon Therapeutics presents data on ACR-2316's tumor cell death mechanisms and early clinical trial results at AACR 2025. Acrivon Therapeutics has announced that it will present findings on ACR-2316 ...

Scientists have discovered a promising new target for cancer treatment by activating a DNA repair enzyme called Tyrosyl-DNA phosphodiesterase 1 (TDP1), potentially paving the way for combination ...

This study aimed to elucidate the role of the Cdk1/p53/p21 feedback loop in the pathogenesis of interstitial cystitis (IC)/bladder pain syndrome (BPS). An IC/BPS cell model was established. Cell ...

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...